FDA Approves New Option for Age-Related Macular Degeneration

The FDA has approved Lucentis (ranibizumab injection) 0.5 mg prefilled syringes for the treatment of wet age-related macular degeneration (AMD) and macular edema following retinal vein occlusion.
_______________________________________________________________________________________________________________________________________________________
RELATED CONTENT
Rehab Therapy Decreases Depression in Patients with AMD
Glaucoma Drops May Help in Refractory AMD
______________________________________________________________________________________________________________________________________________________

The product is the first prefilled syringe to contain vascular endothelial growth factor inhibitor, eliminating several steps in the preparation and administration process. Lucentis was approved for the treatment of wet AMD in 2006.

The most common eye-related side effects include increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure.

—Michael Potts

Reference:

Genentech. FDA approves Genentech’s Lucentis® (ranibizumab injection) prefilled syringe [press release]. October 14, 2016. https://www.gene.com/media/press-releases/14640/2016-10-14/fda-approves-genentechs-lucentis-ranibiz.